{"organizations": [], "uuid": "70b9a1092a4c1be95fdfb3407826d1e1d9f56c37", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "//sc.cnbcfm.com/applications/cnbc.com/staticcontent/img/cnbc_logo.gif", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/01/08/business-wire-bluebird-bio-announces-closing-of-over-allotment-option-in-public-offering.html", "country": "US", "domain_rank": 767, "title": "bluebird bio Announces Closing of Over-Allotment Option in Public Offering", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-09T00:05:00.000+02:00", "replies_count": 0, "uuid": "70b9a1092a4c1be95fdfb3407826d1e1d9f56c37"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/01/08/business-wire-bluebird-bio-announces-closing-of-over-allotment-option-in-public-offering.html", "ord_in_thread": 0, "title": "bluebird bio Announces Closing of Over-Allotment Option in Public Offering", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "CAMBRIDGE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it has issued an additional 277,109 shares of common stock at the public offering price of $185 per share, for total gross proceeds of approximately $51.3 million, pursuant to the partial exercise of the underwriters’ over-allotment option in connection with the company’s previously announced public offering of common stock. After giving effect to this exercise of the over-allotment option, the total number of shares sold by bluebird bio in the public offering was 3,520,353 and gross proceeds of the offering were approximately $651.3 million.\nGoldman Sachs & Co. LLC, BofA Merrill Lynch, J.P. Morgan Securities LLC and Cowen acted as joint book-running managers of the offering.\nThe shares were offered by bluebird bio pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission (SEC). A prospectus supplement relating to the offering was filed with the SEC on December 13, 2017 and is available on the SEC’s website at www.sec.gov . Copies of the prospectus supplement and the accompanying prospectus relating to these securities may also be obtained by contacting one of the following: Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, telephone: (212) 902-1171, facsimile: (212) 902-9316, email: prospectus-ny@ny.email.gs.com ; BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, email: dg.prospectus_requests@baml.com ; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (631) 274-2806 or by fax at (631) 254-7140.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.\nAbout bluebird bio, Inc.\nWith its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and cancer. bluebird bio's gene therapy clinical programs include its Lenti-D ™ product candidate, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin ® product candidate, currently in five clinical studies for the treatment of transfusion-dependent β-thalassemia, also known as β-thalassemia major, and severe sickle cell disease. bluebird bio's oncology pipeline is built upon the company's leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird bio's lead oncology programs, bb2121 and bb21217, are anti-BCMA CAR T programs partnered with Celgene. bb2121 and bb21217 are each currently being studied in Phase 1 trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies with the potential for use across the company's pipeline.\nbluebird bio has operations in Cambridge, Massachusetts, Seattle, Washington, Durham, North Carolina and Europe.\nLentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.\nForward-Looking Statements\nThis release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding bluebird bio’s existing product candidates and research programs. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions, that the preliminary results from our clinical trials will not continue or be repeated in our ongoing clinical trials, the risk of cessation or delay of any of the ongoing or planned clinical studies and/or our development of our product candidates, the risk of a delay in the enrollment of patients in our clinical studies, the risks that the changes we have made in the LentiGlobin drug product manufacturing process or the HGB-206 clinical study protocol will not result in improved patient outcomes, risks that the current or planned clinical studies of the LentiGlobin drug product will be insufficient to support regulatory submissions or marketing approval in the United States and European Union, risks that the current clinical study of Lenti-D will be insufficient to support regulatory submissions or marketing approval in the United States and European Union, the risk that our collaborations, including the collaboration with Celgene, will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed, approved or commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our annual report on Form 10-K and our most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180108006795/en/\nbluebird bio, Inc.\nInvestors\nElizabeth Pingpank, 617-914-8736\nepingpank@bluebirdbio.com\nor\nMedia\nStephanie Fagan, 201-572-9581\nsfagan@bluebirdbio.com\nSource: bluebird bio, Inc.", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=51739723&newsitemid=20180108006795&lan=en-US&anchor=www.sec.gov&index=1&md5=378384f735b1421907546662f7469fc1", "http://www.businesswire.com/news/home/20180108006795/en/"], "published": "2018-01-09T00:05:00.000+02:00", "crawled": "2018-01-09T09:36:37.006+02:00", "highlightTitle": ""}